BioMaxima S.A. (FRA:944)

Germany · Delayed Price · Currency is EUR

1.870

-0.014 (-0.74%)

Last updated: Jun 26, 2026, 3:25 PM CET

-29.43% (1Y)

Market Cap	9.33M -34.7%
Revenue (ttm)	14.43M +15.2%
Net Income	24.89K -80.4%
EPS	0.01 -80.4%
Shares Out	n/a
PE Ratio	374.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.912
Previous Close	1.884
Day's Range	1.870 - 1.912
52-Week Range	1.858 - 3.350
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About BioMaxima

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in v... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus

Founded 1997

Employees 135

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 944

Financial Performance

In 2025, BioMaxima's revenue was 60.90 million, an increase of 15.24% compared to the previous year's 52.85 million. Earnings were 105,000, a decrease of -80.37%.

Financial numbers in PLN Financial Statements